LifeSci Capital analyst Sam Slutsky has maintained their bullish stance on PYXS stock, giving a Buy rating yesterday.
Sam Slutsky has given his Buy rating due to a combination of factors including Pyxis Oncology’s strategic focus and promising clinical developments. The company is advancing its PYX-201 program, which targets extra-domain B of fibronectin in the tumor stroma, showing an efficacy signal in head and neck squamous cell carcinoma (HNSCC) patients. This positive signal has led Pyxis to plan further development in this patient population, as well as in other solid tumors such as HR+/HER2- breast cancer and triple-negative breast cancer.
Furthermore, Pyxis has outlined a structured approach for its HNSCC plans, including combination therapy with Keytruda and monotherapy in specific patient groups, with significant data releases expected in the coming years. The company’s recent FDA Fast Track Designation for a particular patient population and its financial position, with over 1.5 years of cash runway, also contribute to the optimistic outlook. These factors combined suggest potential growth and value, supporting Slutsky’s Buy recommendation.
In another report released yesterday, Jefferies also maintained a Buy rating on the stock with a $6.00 price target.